JAMES C YAO to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications JAMES C YAO has written about Randomized Controlled Trials as Topic.
Connection Strength
0.918
-
Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist. 2013; 18(5):525-32.
Score: 0.240
-
In reply. Oncologist. 2013; 18(11):1240-1.
Score: 0.235
-
Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. Cancer. 2021 Aug 01; 127(15):2674-2682.
Score: 0.104
-
Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. BMC Med Res Methodol. 2018 12 12; 18(1):169.
Score: 0.089
-
From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol. 2015 Nov 01; 33(31):3583-90.
Score: 0.070
-
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 01; 29(7):934-43.
Score: 0.051
-
Perspectives in the development of novel treatment approaches. Tumori. 2010 Sep-Oct; 96(5):858-73.
Score: 0.050
-
Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol. 2002; 13 Suppl 4:7-12.
Score: 0.027
-
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol. 2021 Aug; 17(24):3151-3162.
Score: 0.026
-
Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas. 2021 02 01; 50(2):130-137.
Score: 0.026